Clik here to view.
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory...
SAN DIEGO Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, today announced the company had raised $70 million in...
View ArticleClik here to view.
MagBio Genomics Inc.面向Mawi iSWAB-RNA v2开发用于Thermofisher KingFisher™...
加州海沃德 (美国商业资讯)–专注于开发生物采样创新技术的生物技术公司Mawi DNA Technologies宣布，MagBio Genomics通过其HighPrep™ Total RNA Isolation Kit-iSWAB™成功开发出一种面向iSWAB-RNA v2且用于Thermofisher KingFisher™ Flex平台的自动RNA纯化方法。 Mawi DNA...
View ArticleClik here to view.
Genetron Health Announces Strategic Partnership with Siemens Healthineers to...
SHANGHAI Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests,...
View ArticleClik here to view.
PharmaEssentia Resubmits Application to the U.S. FDA For Ropeginterferon...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corp. (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific...
View ArticleClik here to view.
武田2020财年业绩保持韧性，利润率和现金流均表现强劲；基础营收增长预计在2021财年加速
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TOKYO:4502) (NYSE:TAK)（简称“武田”）今天公布了2020财年财务业绩（截至2021年3月31日）。 武田总裁兼首席执行官CHRISTOPHE WEBER表示：...
View ArticleClik here to view.
インサイトとモルフォシス、びまん性大細胞型B細胞リンパ腫の第一選択治療としてのタファシタマブ併用療法を評価する第3相frontMIND試験で最初の患者が投...
独プラネッグ & ミュンヘン & 米デラウェア州ウィルミントン （ビジネスワイヤ） — インサイト（NASDAQ:INCY）とモルフォシス（FSE:MOR、NASDAQ:...
View ArticleClik here to view.
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side...
CAMBRIDGE, Mass. & SHANGHAI Detailed results from the Phase III AENEAS trial showed that treatment with aumolertinib resulted in a clinically significant improvement in progression-free survival...
View ArticleClik here to view.
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV®...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from two clinical...
View ArticleClik here to view.
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib...
View ArticleClik here to view.
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally...
View ArticleClik here to view.
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the...
OSAKA, Japan Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has...
View ArticleClik here to view.
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
武田呈报mobocertinib的最新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)（简称“武田”）今天发布mobocertinib...
View ArticleClik here to view.
ASCO21で発表するメルクのオンコロジーポートフォリオのデータは、がん治療における大きな前進を明瞭に示す
独ダルムシュタット （ビジネスワイヤ） — 本リリースは英国、米国、カナダのメディア向けを意図しておりません。...
View ArticleClik here to view.
武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，2期OPTIC（Optimizing Ponatinib Treatment In...
View ArticleClik here to view.
NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial...
BELOIT, Wis. & SYDNEY NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and...
View ArticleClik here to view.
知临集团：针对金黄色葡萄球菌的ALS-4临床I期试验中期分析取得阳性进展，针对神经母细胞瘤的SACT-1新药临床试验申报前准备取得阳性进展
纽约和伦敦和巴黎 (美国商业资讯)–监管新闻： 临床阶段生物制药公司知临集团（Aptorum Group...
View Article